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Breast cancer is the second largest killer disease among 
women globally. Annually approximately 48,000 women die of 
breast cancer. Breast cancer patients are at high risk of developing 
malnutrition from the underlying disease as well as from various 
drug regimen, chemotherapy and or radiotherapy interventions. 
As we work for personalized medicine for breast cancer, a 
personalized nutrition for breast cancer patients is much needed 
for their wellbeing both physiologically and psychologically. 
Most rather than all, of the treatment regimens possesses a 
concourse of side effects. An effective personalized nutritional 
therapy during and after cancer treatment leads to better quality of 
life for the breast cancer patients. Clinical trials are pivotal for any 
recommendations to be used at the commercial level upon 
approval of Food & Drug Administration. Several clinical trials 
have been carried out and many are now undertaken to come up 
with a significant upshot conclusion based on primary and 
secondary outcomes to show the after effects of particular nutrient 
supplements by increasing the overall survival or any other 
physiological upregulated / downregulated manifestation leading 
for a disease free survival. Docosahexaenoic acid and glutamine 
nutritional supplement has been reported to have beneficial effect 
for breast cancer patients in different clinical trials. 
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Designing a personalized with a precision for breast 
cancer patients in a truly clinical nutrition intervention 
is considered as the cutting-edge technology solution 
for the disease-free survival of the breast cancer 
patients. The oncologist in such a therapy has to work 
together with the nutritionist to reach up to the patient, 
patient’s caretakers and also to a multiconvergence 
team comprising of data analysts, nursing fraternity and 
health counsellors to provide an adequate nutritional 
assessment based on the breast cancer patient’s 
preference to come up with the intervention follow-
up
1,2
. Several start-ups for breast cancer therapy and 
prognosis work on convergence technology as focus 
groups for the reduction of breast cancer mortality
3
. 
Metformin a well-known drug for diabetes is now in 
the clinical trials for breast cancer therapy, as we want 
a solution from all directions of technology 
development and developers
4
. In terms of breast cancer 
diagnosis, Raman spectroscopy is in the pipeline for 
more accurate early detection of breast cancer
5
.  
Materials and Methods 
Docosahexaenoic acid 
Dietary docosahexaenoic acid (DHA) (Fig. 1A) 
can make mammary tumours more sensitive to anti-
cancer agents. Omega-3 fatty acids especially DHA 
belongs to polyunsaturated fatty acids category which 
are long-chained. Their long chain are basically and 
most predominantly alpha-linolenic acid, which 
possess 18 carbon chain back bone. DHA is 
abundantly found in sea foods. Normal physiology of 
a human being produces DHA under regular and 
normal metabolic conditions, upon triggering the 
normal physiology due to cancerous condition leading 
to morbidity, the quite normal metabolic cascade goes 
hayward resulting in cachexia. Absorption of DHA by 
the human system and these nutrient molecules 
reaching out for the cellular uptake is without an iota 
of doubt it is only by direct intake and consumption of 
food containing rich sources of DHA. Levels of DHA 
in blood plasma concentration can be worked upon by 
the nutritional food regime to the breast cancer 
patients. Double the plasma concentration of DHA 
has also been achieved by a scheduled nutritional 
menu for breast cancer patients. This increase in 
blood plasma DHA concentration leads to fecundation 
of lipids present in plasma membrane. 
Glutamine 
Plethoric quantum of Glutamine (Fig 1B) is freely 
available in as a free amino acid in the biological 
fluids and specimens especially blood plasma and 
tissue. Breast cancer consociated complexities 
primarily cachexia and dermal damage post 




radiotherapy is very much associated with shrivelled 
concentration amounts of amino acids in the blood 
circulation, especially Glutamine. By increasing the 
blood plasma glutamine concentration, acts as a 
immune booster for some subtypes of breast cancer.  
 
Results and Discussion 
Several clinical trials have been carried out, 
recruiting and many in the pipeline for the effect of 
DHA on the clinical outcomes in a modified primary, 
secondary and exploratory outcomes. The outcomes 
of a clinical trial need to be quantitative and 
statistically significant for the elucidation of a clinical 
trial. There are several outcome definitions of a 
clinical trial namely, disease free survival, overall 
survival, variation of a biochemical biomarker, 
recurrence incidence and so on. 
Generally, for a nutritional supplement-oriented 
chemotherapy, regular drug regimen is followed for 
both the standard (control) ARM and the test ARM. 
ARM-1 being provided with a placebo and ARM-2 to 
be provided with DHA rich nutritional supplement in 
the form a food intake rather as a therapeutic. 
Enhancement of chemothrapy efficacy was 
evaluated
6
 by carrying out a double-blind, phase II 
randomized clinical trial. Total numebr of recruiters 
were 52 in total with an expected 10% dropout. 
ARM-2 (n = 23) being the test ARM were provided 
with 4.4 g/day DHA orally. The placebo ARM-1  
(n = 23) was prescribed with the same quantity and 
amount as ARM -2 but of vegetable oil which are rich 
in fat supplement. Differences in Ki67 labelling index 
identified by biopsy studies (core needle) before 
chemotherapy was the primary outcome with several 
biochemical biomarkers variation with respect to the 
placebo ARM were the exploratory outcomes one of 
the chief augmenting the primary outcome being 
DHA plasma phospholipid content. 
In ARM-2 the test ARM having the DHA 
supplementation, one other evaluation was also 
carried out as an inter ARM elucidation upon a 
statistically significant proposition was observed 
wherein the difference in DHA the factors influencing 
the incorporation upon a comparison (low versus high 
incorporators) possible factors that predict 
incorporation was also studied. As this clinical trial is 
still underway, interesting results are awaited 
(Clinical Trial Registration Number NCT03831178).
7
 
In another clinical trial (Phase II)
8
 involving 25 
breast cancer patients (n = 25) were studied for the 
effect of DHA nutritional supplement. This phase II 
clinical trial recruited metastatic breast cancer patients 
undergoing anthracycline chemotherapy drug regimen 
for the elucidation of the efficacy and safety intake 
amounts of nutritional supplement of DHA. In 
addition, among the twenty five recruited breast 
cancer patients, twelve breast cancer patients had 
received tamoxifene as an adjuvant hormonal therapy. 
The median age is being 52 years of old in the range 
of 32 to 71. Minimum dosage of 1.8 g/day of DHA is 
needed wherein less than this stipulated concentration 
will not elicit a physiological and biochemical 
incorporation of the intake of DHA into tissue cell 
membrane phospholipids. This is a single ARM 
clinical trial. All the breast cancer patient recruiters 
were prescribed nutrient supplement DHA enriched 
capsules containing triglyceride oil of algal origin 
(44% DHA providing minimum 0.2 g DHA). Daily 
dosage of nine capsules which is representing 0.2 g of 
DHA for a daily intake is surmounting a needed 
intake of 1.8 g/day of DHA.  
In this open-label single-arm phase II study, single 
inter ARM strategy was used for the evaluation of the 
primary and secondary end points. Patient distribution 
according to the extent of DHA increase was 
segregated as Low DHA incorporators (L-DHA) and 
High DHA incorporators (H-DHA). Different primary 
and secondary end points are considered for clinical 
trials. In this clinical trial, response rate was one of 
the primary end point and safety profile was the other 
primary end point. Time to Progression (TTP) and 
overall survival (OS) were the secondary end points.  
Response was defined as complete response (CR), 
partial response (PR), stable disease (SD) and / or 
progressive disease (PD).  
 
Objective Response Rate  ORR =  
CR + PR
n










Clinical Benefit  CB =  
CR + PR + SD
n
                  … (2) 
 
Where, n = number of patients. ORR was calculated 
and found to be 44% (95% CI, 24.5–63.5) (1 CR and 
10 PR) with eleven SD cases and three PD cases. CB 
was also calculated and observed to be 88%.  
One of the secondary endpoint namely, OS was the 
most impressive finding in this clinical trial using 
metastatic breast cancer patients. TTP was significantly 
higher in patients with an H-DHA incorporation (8.7 
months vs 3.5 months) in patients with L-DHA 
incorporation), suggesting a greater efficacy of 
chemotherapy (Fig 2A) .OS was almost doubled in 
patients with H-DHA incorporation (34 months vs  
18 months) (Fig 2B).  
Improvement of treatment outcomes for breast 
cancer patients who were prescribed and underwent 
radiotherapy, certain dermal damages and injuries 
could be protected or at the minimization level has 
been studied using glutamine as a nutritional 
supplement. Dermal texture and level of cosmetic 
disfiguration has been quantified. Recurrence of these 
dermal effects was also studied. A positive trend in the 
direction of subsiding effects of skin radiation injury 
and pain was observed. 
In this randomized double-blind study
9
 totally 
seventeen breast cancer patients for whom radiotherapy 
as the first line of treatment for their health issue were 
recruited. ARM -1 the control ARM having n = 8 were 
placed in the placebo Arm and rest n = 9 were placed 
in the test ARM -2. Dextrose was given for ARM -1 
and Gln for ARM -2. The patients were randomized to 
receive one of the oral nutritional supplement which 
was thoroughly mixed and shaken in a cold liquid of 
the preference of the recruiters either pure amino acid 
L-Gln powder (0.5 g/kg/d) or dextrose, 25 g/d). 
Radiation Therapy Oncology Group (RTOG) scales 
were used for the evaluation of radiation injury 
occurred due to radio therapy intervention. In a scale of 
0 – 4 for acute radiation morbidity scoring criteria now 
changed to acute necrosis. Cosmetic scores were also 
evaluated. Other biomarkers and biochemical 
parameters were also quantified like blood glutamine, 
glutathione (GSH) and serum protein profiling.  
 
Conclusions 
Many more clinical trials in nutritional cachexia 
oncology are needed especially for breast cancer 
patients to reduce the mortality. Henceforth, a holistic 
personalized care is mandatory to reduce breast 
cancer mortality by 50% by 2035.  
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Fig. 2 — (A) Time To progression (TTP) and (B) profile of ARM -
1 and ARM -2 (Ref. 8) 
 
 
